Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Avenge Bio Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://avengebio.com/
Year Founded: 2019
Status: Private
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | Aug 3, 2024
Management Tracks
Dannielle Appelhans to lead Cour
Plus: Context hires Ullmann, Andreas, and updates from Galectin, Exagen, Candid, Amgen and Hummingbird
BioCentury | Sep 15, 2023
Discovery & Translation
Mini Cas protein iterations; plus Moderna’s Lassa virus vaccine and more
BioCentury’s roundup of translational innovations
BioCentury | Jan 6, 2023
Management Tracks
Singhal to lead development at Biogen as company splits R&D
Plus: Baumal named CMO at Apellis, and updates from Pheast, Sofinnova Partners, GE, Lexeo and more
BioCentury | Jan 4, 2023
Management Tracks
Ex-Checkmate CEO Bash to lead ZielBio
Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
BioCentury | Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
BioCentury | Feb 23, 2022
Management Tracks
Gerngross resigns as Adagio CEO
Plus Shah steps down as CMO at Karyopharm; updates from Meridian, HanAll and more
BioCentury | Sep 24, 2020
Finance
Data Bytes: record fund for Longitude follows rush of deals, IPOs
On the back of seven liquidity events in the past four months, Longitude Capital has closed its largest fund to date at $585 million. Managing Director Patrick Enright told BioCentury Longitude
Items per page:
1 - 8 of 8